ENTPD1 and neoplasm: Ectonucleotidases (CD39 and CD73) hydrolyze exATP to ADO and increased ADO inhibits the anti-tumor function of innate immune cells and effector T cells (Teff, CD4+ and CD8+), and monocyte differentiation into associated tumor macrophages 2s (72).